A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023,[1] and also subsequently identified in Russia.[2] It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs.
Identifiers | |
---|---|
| |
CAS Number |
|
Chemical and physical data | |
Formula | C23H30N2OS |
Molar mass | 382.57 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
- ^ Yurchenko RA, Yurchenko LV, Galetskaya IA, Novitsky MV, Pavlovets YS (February 2024). Psychoactive products market observation. Trend analysis (Report) (in Russian). Aipsin. doi:10.13140/RG.2.2.10176.92163.